CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03875313
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:47.838445+00:00
Published At: 2022-02-17T00:00:00+00:00
Record Updated At: 2022-02-17
Results Posted At: 2022-02-17
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Solid Tumor", "Clear Cell Renal Cell Carcinoma", "TNBC - Triple-Negative Breast Cancer", "Colorectal Cancer", "CRC", "RCC", "ccRCC"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-02-17"
protocolSection.identificationModule.nctId: "NCT03875313"
protocolSection.identificationModule.officialTitle: "A Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2022-02-17"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.